- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- The 10 Poorest States in America
Allergan blazed a trail when its wrinkle-fighting treatment Botox opened up the facial aesthetics market. Now Kythera is attempting to follow that path with its double-chin drug Kybella.
Kythera has high expectations for the targeted launch of its FDA-approved double chin injection Kybella in the second half of 2015, said the company's CEO Keith Leonard.
Bathing-suit season is fast approaching and Medifast CEO Michael MacDonald says his weight-loss company is ready to impress the gawkers on Wall Street.
Medifast finished the first quarter ahead of where it wanted to be and the weight loss company is now gearing up for a strong second half, says CEO Michael MacDonald.
PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller.
‘Shadow Work’ includes all the unpaid tasks we do on behalf of businesses and organizations every day from pumping gas to bagging groceries, said Craig Lambert, author of 'Shadow Work.'
IMAX's international expansion and new laser technology will continue to drive the company's stock higher, said Michael Balkin, Portfolio Manager for the William Blair Small Cap Fund.
Historically speaking Wall Street banks are indeed being stifled by burdensome regulations in the aftermath of the 2008 crash, but the kinks will eventually be worked out.
Elon Musk may be a brilliant and intense businessman, but don't put him next to Thomas Edison or Steve Jobs just yet, says Ashlee Vance, author of 'Elon Musk.'
Establishing simple guidelines or rules takes the emotion out of investing and that loss of emotional control is a big reason why people lose money in the market.